Coffee vs Medifast
JVA and MED side by side, both in food and kindred products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JVA and MED compare
Medifast is the larger company, worth 5.0 times as much as Coffee ($145M against $28.9M).
Coffee grew revenue faster over the last twelve months (8.2% versus −30.3% for Medifast).
Coffee keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with −13.6% at Medifast.
Coffee pays a dividend yielding 1.6%; Medifast does not pay one.
Coffee scores higher on the StockData Score (17 against 10 for Medifast), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JVA | MED |
|---|---|---|
| Size and price | ||
| Market cap | $28.9M | $145M |
| Share price | $5.07 | $12.97 |
| Change, 1 year | 27.1% | 11.5% |
| Change, 5 years | 12.7% | −94.1% |
| Beta (5Y) | 0.56 | 0.71 |
| Employees | 92 | 380 |
| StockData Score | ||
| Total score | 17 (better) | 10 |
| Valuation score | 6 (better) | 3 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 3 | 6 (better) |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 6.1× | – |
| P/S | 0.3× (better) | 0.5× |
| P/B | 0.9× | 0.8× (better) |
| EV/EBITDA | 3.9× | – |
| P/FCF | 3.6× | – |
| FCF yield | 27.6% (better) | −2.7% |
| Fair value | $13.10 | $35.80 |
| Margin of safety | 61.3% | 63.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | −30.3% |
| Revenue growth, 5Y average | 7.8% (better) | −16.2% |
| Net income growth (TTM) | 154% (better) | −16573% |
| EPS growth (TTM) | 159% (better) | −37000% |
| Profitability | ||
| Gross margin | 19.9% | 69.2% (better) |
| Operating margin | 6.0% (better) | −11.6% |
| Net margin | 4.9% (better) | −13.6% |
| FCF margin | 8.2% (better) | −1.3% |
| Return on equity | 16.3% (better) | −20.7% |
| Return on invested capital | 18.2% (better) | −110% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 24.0× | – |
| Current ratio | 4.14 | 4.82 (better) |
| Altman Z-score | 6.13 (better) | 3.83 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.6% (better) | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 1.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 18.7% | 73.9% |
| Held by insiders | 5.4% | 12.3% |
| Insider net buying, 12 months | – | $1.5M |
| Short interest, % of float | 0.50% | 13.2% |
Go deeper
- JVA stock overview
- JVA income statement
- JVA valuation and score
- MED stock overview
- MED income statement
- MED valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.